Mesothelioma Vaccine Enters Phase 2 Testing
| |

Mesothelioma Vaccine Enters Phase 2 Testing

The makers of a new cancer vaccine say they have enrolled the first mesothelioma patients in a study that will combine their drug with chemotherapy against this virulent cancer. The drug, currently known as CRS-207, is manufactured by Aduro Bio Tech, Inc. According to a company press release, CRS-207 is based on an attenuated (made less potent) version of Listeria monocytogenes, bacteria found in soil and water than can cause the food borne illness, Listeriosis. To make CRS-207, scientists at Aduro genetically modified the Listeria monocytogenes in order to produce a powerful immune response against cells that produce mesothelin. Mesothelin is a tumor-associated antigen produced by several types of cancer cells, including mesothelioma cells. Because it works in conjunction with the body’s…

Immunotherapy for Mesothelioma Shows Promise
|

Immunotherapy for Mesothelioma Shows Promise

Despite the continuing efforts of researchers around the world, there is currently no standardized cure for mesothelioma. The asbestos-linked cancer is fast-growing and often resistant to conventional therapies. But a growing number of studies have pointed to the value of unconventional treatments like immunotherapy for mesothelioma. Immunotherapy refers to any treatment protocol which aims to harness the body’s own immune system to fight cancer cells.  In a recent article in The Lancet Oncology, two National Cancer Institute researchers summarized some of the most promising immunotherapy approaches now being investigated for mesothelioma: In dendritic cell-based immunotherapy, dendritic cells are harvested from the patient. Outside the body, these cells are stimulated to activate a cytotoxic response against cancer cells.  When they are…

Immunotherapy May Improve Chemotherapy for Mesothelioma
| |

Immunotherapy May Improve Chemotherapy for Mesothelioma

A treatment designed to inhibit a cell protein called CTLA-4 may improve the effectiveness of chemotherapy for mesothelioma. Chemotherapy is considered a front-line treatment for mesothelioma, although it is only moderately effective.  Because mesothelioma is a highly aggressive cancer of the mesothelium, chemotherapy is often used as part of a multimodality therapeutic approach. Increasingly, immunotherapy, which involves manipulation of the genes and immune system, is also part of the treatment approach. CTLA-4 is the name for both a protein and the gene that is responsible for producing it.  A recent published study tested the theory that knocking down cellular production of the CTLA-4 protein could slow tumor growth and stimulate the immune system between rounds of chemotherapy. To test the…

Mesothelioma Vaccine Jump Starts Immunity
| |

Mesothelioma Vaccine Jump Starts Immunity

Scientists studying a vaccine for mesothelioma have published some of their most important preliminary data in the respected medical journal Lung Cancer. Mesothelioma, a cancer of the organ linings caused by asbestos exposure, is highly resistant to conventional treatments.  Not only does it grow quickly, but its shape makes detection and removal difficult. Unlike some other types of solid tumors which may grow in a mass, mesothelioma tumors tend to spread out in a sheet-like formation across membranes. The UK scientists have been experimenting with a new method for targeting and destroying mesothelioma tumors, regardless of their shape. 5T4 is an antigen overexpressed by several kinds of cancer cells. The researchers tested for 5T4 in mesothelioma cells taken from 11 lab-grown cell…

Mesothelioma ‘Triple Treatment’ May Jump Start Killer Cells
| |

Mesothelioma ‘Triple Treatment’ May Jump Start Killer Cells

New mesothelioma research from Harvard University suggests that if one type of immunotherapy is effective against mesothelioma, three types might be even more effective. Immunotherapy involves manipulating the immune system to fight disease. Some types of cancer, including mesothelioma, take hold in the body in part by ‘shutting down’ the natural immunotoxins, or cell killers, that would normally attack them. Now, scientists are working with a number of molecules designed to jump start the immune system and help it recognize, target, and even ‘remember’ invading mesothelioma cancer cells. Using a mouse model of mesothelioma, the Harvard researchers investigated the roles of three factors effecting immunity: regulatory T-cells, intratumoural transforming growth factor (TGF)-â and cytotoxic T lymphocyte-associated antigen-4 (CTLA4). The researchers…

Harnessing T-Cells to Fight Mesothelioma
| |

Harnessing T-Cells to Fight Mesothelioma

Cancer researchers in Australia are harnessing the power of disease-fighting T-cells in the ongoing battle with mesothelioma. Mesothelioma is a virulent cancer of the membrane that surrounds the lungs and lines the abdomen. The response of the body’s immune system to mesothelioma and other cancers is complex. Mesothelioma tumors in mice and people produce large numbers of Regulatory (Treg) T cells. While Treg cells are typically thought of as one of the body’s ways of fighting disease, the latest research suggests that, in some cases, turning these cells ‘off’ might be more effective against cancer than letting them do their job. In the newest study of Treg cells, they were shown to act as important “mediators” of the body’s anti-tumor…

Immune System May Help Fight Mesothelioma
| |

Immune System May Help Fight Mesothelioma

Proteins and toxins produced by the body’s own immune system could prove to be powerful weapons in the fight against malignant mesothelioma. Manipulating the immune system to fight cancer is known as immunotherapy. One type of immunotherapy is utilizing natural immunotoxins, or cell killers, produced by the white blood cells to attack tumors. Preliminary data shows that a protein produced by these cells called interleukin-4 or IL-4, may have potent cancer-fighting properties. Researchers with the Pacific Heart Lung & Blood Institute in California are planning studies to test the toxin’s value as a way to combat mesothelioma. Their first challenge will be to produce enough IL-4 to conduct tests. When enough of the immunotoxin can be synthesized according to FDA…

Future Mesothelioma Treatment
| |

Future Mesothelioma Treatment

A combination of immunotherapy and traditional  may be more effective than either treatment alone against mesothelioma, according to a recent analysis published in the journal, Tissue Antigens. Mesothelioma is one of the most difficult cancers to treat, and the prognosis is often poor. Surgery and chemotherapy are the standard mesothelioma treatments, but even with these therapies many patients do not live more than a year after their diagnosis. A newer treatment option is immunotherapy, which enhances the immune system response to help the body attack cancer cells. Because mesothelioma engages the immune system, immunotherapy would appear to be a promising treatment strategy for this cancer. However, studies conducted so far on immunotherapy for mesothelioma have yielded disappointing results. Combining immunotherapy…